Atopic Dermatitis: Upadacitinib Effective in Two Phase 3 Trials ...Middle East

Medscape - News
The JAK inhibitor, currently approved for rheumatoid arthritis, yielded improvements in skin clearance, itch, and quality of life for nearly 1700 patients with moderate to severe disease. Medscape Medical News

Hence then, the article about atopic dermatitis upadacitinib effective in two phase 3 trials was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Atopic Dermatitis: Upadacitinib Effective in Two Phase 3 Trials )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News